NIH Licensing Opportunity:
A Vaccine to prevent virally-induced damage seen in kidney transplants
One Million Solutions in Health™ has established a one-of-a-kind, new partnership with the United States’ National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) to increase awareness and understanding of NIH technologies by potential partners in the life science and healthcare industries.
This provides you with a front-row seat to hear about new technology and science from various scientists at the NIH. This is also your opportunity to participate in our proprietary Signature Square process, where end-users can evaluate the technology, ask questions and provide feedback directly to the scientist.
Join us for this webinar that will introduce a ground-breaking vaccine that can potentially prevent virally-induced damage seen in kidney transplants.
A great majority of healthy adults chronically shed polyomavirus virions in their urine and from the surface of their skin. Although these infections generally aren’t known to cause symptoms in healthy individuals, polyomavirus can cause a cascade in immunosuppressed individuals, such as those undergoing kidney transplants, leading to acute rejection of the kidney. This cascade produces starts with the virus initially replicating in the distal tubular epithelial cells, leading to necrosis and initiation of local damage and inflammation.
Studies were conducted on two families of cancer-causing viruses with circular DNA genomes, and it was found that the polyomavirus coat protein spontaneously self-assembles into virus-like particles (VLPs) that closely resemble the native virion. These VLPs were found to be exceptionally potent immunogens in humans.
The NCI has recently been allowed patents covering the use of VLPs as vaccines targeting two human polyomaviruses known as JCV and BKV. During this webinar, NCI Senior Investigator, Chris Buck will describe the application of a polyomavirus VLP vaccine to the prevention of JVC and BKV-induced kidney damage in transplant patients.
THE OPPORTUNITY IS TO VACCINATE EACH INDIVIDUAL, AS SOON AS THEY JOIN THE KIDNEY TRANSPLANT WAITLIST.
VLPs are generally safe, and patients have few options for preventing rejection in the kidney transplant process, therefore the market potential is strong.
The Signature Square process is part of our Consortium infrastructure. Current member companies in the Technology Evaluation Consortium and SafeTEC include organizations like AstraZeneca, AbbVie, Amgen and Allergan, along with many others, including scientists, clinicians and investors in organizations around the world who help to evaluate this technology.
This is your opportunity to ask questions and provide feedback directly to the scientists by taking part in this Signature Square program.
Christopher B. Buck, Ph.D.
National Cancer Institute
Center for Cancer Research (CCR)
Dawn Van Dam
Executive Director & CEO
One Million Solutions in Health™
REGISTER ME FOR THIS SIGNATURE SQUARE EVENT: Click HERE